Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2013 - 2026)

Amphastar Pharmaceuticals' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$16.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 259.65% year-over-year to -$16.7 million; the TTM figure through Mar 2026 stood at -$97.5 million (up 24.78% YoY), while the FY2025 annual figure was -$70.3 million, up 43.7% from the prior year.
• Cash from Investing Activities was -$16.7 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$60.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $15.2 million in Q1 2024 to a low of -$508.6 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged -$52.6 million across 5 years, with a median of -$16.7 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 44899.56% in 2023, then jumped 340.6% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$229000.0 in 2022, then sank by 44899.56% to -$103.0 million in 2023, then surged by 65.38% to -$35.7 million in 2024, then slumped by 69.77% to -$60.6 million in 2025, then jumped by 72.37% to -$16.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$16.7 million (Q1 2026), -$60.6 million (Q4 2025), and -$19.6 million (Q3 2025), per Business Quant data.